Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Q/C Technologies, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 28 | 41 | +13 |
| Shares | 5.80M | 4.47M | −1.34M (−23.0%) |
| Value | $41.8M | $27.1M | −$14.7M (−35.2%) |
New holders (15)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 124,000 | $751.0K | 0.21% |
| Millennium Management LLC | 61,470 | $373.0K | 0.00% |
| 683 Capital Management, LLC | 59,410 | $360.0K | 0.02% |
| Qube Research & Technologies Ltd | 21,674 | $131.0K | 0.00% |
| Jane Street Group, LLC | 17,908 | $109.0K | 0.00% |
| Taylor & Morgan Wealth Management, LLC | 17,836 | $108.0K | 0.09% |
| Goldman Sachs Group Inc | 16,194 | $98.0K | 0.00% |
| HRT Financial LP | 15,851 | $96.0K | 0.00% |
| Boothbay Fund Management, LLC | 13,690 | $83.0K | 0.00% |
| Ergoteles LLC | 11,800 | $72.0K | 0.00% |
| JPMorgan Chase & Co | 8,934 | $54.0K | 0.00% |
| Simplex Trading, LLC | 8,435 | $51.0K | 0.00% |
| Level Financial Advisors, Inc. | 200 | $1.00K | 0.00% |
| TD Waterhouse Canada Inc. | 27 | $193 | 0.00% |
| Cornerstone Advisory, LLC | 2 | $0 | 0.00% |
Sold out (2)
Institutions that held Q/C Technologies, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| NorthRock Partners, LLC | 1,354,004 | $9.75M |
| Invesco Ltd. | 235,194 | $1.69M |